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ABSTRACT In a screen for compounds that inhibit infectivity of the obligate intracellular pathogen Chlamydia trachomatis, we
identified the 2-pyridone amide KSK120. A fluorescent KSK120 analogue was synthesized and observed to be associated with the
C. trachomatis surface, suggesting that its target is bacterial. We isolated KSK120-resistant strains and determined that several
resistance mutations are in genes that affect the uptake and use of glucose-6-phosphate (G-6P). Consistent with an effect on
G-6P metabolism, treatment with KSK120 blocked glycogen accumulation. Interestingly, KSK120 did not affect Escherichia coli
or the host cell. Thus, 2-pyridone amides may represent a class of drugs that can specifically inhibit C. trachomatis infection.
IMPORTANCE Chlamydia trachomatis is a bacterial pathogen of humans that causes a common sexually transmitted disease as
well as eye infections. It grows only inside cells of its host organism, within a parasitophorous vacuole termed the inclusion. Lit-
tle is known, however, about what bacterial components and processes are important for C. trachomatis cellular infectivity.
Here, by using a visual screen for compounds that affect bacterial distribution within the chlamydial inclusion, we identified the
inhibitor KSK120. As hypothesized, the altered bacterial distribution induced by KSK120 correlated with a block in C. trachoma-
tis infectivity. Our data suggest that the compound targets the glucose-6-phosphate (G-6P) metabolism pathway of C. trachoma-
tis, supporting previous indications that G-6P metabolism is critical for C. trachomatis infectivity. Thus, KSK120 may be a use-
ful tool to study chlamydial glucose metabolism and has the potential to be used in the treatment of C. trachomatis infections.
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Chlamydia trachomatis is the causative agent of many sexuallytransmitted diseases (1), as well as of trachoma, a chronic eye
infection (2). Without antibiotic treatment, C. trachomatis infec-
tions of the female genital tract can lead to infertility, a major
public health concern (3). Although chlamydial infections are
treatable with currently available antibiotics, treatment failures
occur (4) and there is evidence for lateral transmission of antibi-
otic resistance in Chlamydia species of veterinary importance (5).
Potential alternative antichlamydial treatment strategies may in-
clude compounds that target specific virulence factors to limit
bacterial proliferation and prevent disease while avoiding disrup-
tion of the normal bacterial flora (6–8). Such strategies may help
reduce the development of resistance to classical antibiotics.
Chlamydia spp. are difficult to study because of their obligate
intracellular lifestyle, and methods for routine molecular genetic
manipulation of this organism are in their infancy. Chemical
genetics provides an alternative approach to study Chlamydia
spp., and other, less-tractable microbial pathogens, by allowing
temporal and quantitative control of the function of a gene prod-
uct through the use of small molecules (9). Such molecules can
provide novel insights into molecular mechanisms of virulence
and can also serve as candidates for the design of better thera-
peutics.
Chlamydiae have a distinctive developmental cycle that in-
volves a transition between two forms. The elementary body (EB)
is the infectious form that attaches to and invades target epithelial
cells. The EB then transitions to a reticulate body (RB) form,
which proliferates within the expanding parasitophorous vacuole,
termed the inclusion (10).Midway through the intracellular cycle,
RBs begin to transition back to the infectious EB form and are
eventually released to the surrounding milieu to infect new host
cells (11, 12).
In this study, we conducted a visual screen to identify
2-pyridone inhibitors that impaired C. trachomatis infectivity.
From this screen, compound KSK120 was identified, and after
selection and isolation of KSK120-resistant strains, resistance
point mutations were mapped to genes involved in glucose-6-
phosphate metabolism.
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RESULTS AND DISCUSSION
Compound KSK120 blocks C. trachomatis infectivity. On the
basis of previous observations that 2-pyridone carboxylic acids
can block biofilm formation of E. coli (13, 14), as well as our recent
findings showing that 2-pyridones have the ability to block infec-
tion of the human intracellular pathogen Listeria monocytogenes
(unpublished observation), we were prompted to investigate a
potential effect on chlamydial infectivity. Therefore, we screened a
library of 61 2-pyridone compounds with various substitutions
around a 2-pyridone central scaffold (Fig. 1A; see also Table S1 in
the supplemental material) for their ability to affect intracellular
infection by C. trachomatis serovar LGV-L2. To identify com-
FIG 1 Compound KSK120 has selective anti-C. trachomatis activity that blocks its infectivity. (A) Compounds synthesized with substituent variations
decorating the 2-pyridone central scaffolds. See Table S1 in the supplemental material for a complete list of compounds tested. (B) HeLa cells infected with
C. trachomatis serovar LGV-2were treated for the entire infectionwith 10MKSK120 orDMSO, fixedwithmethanol at 44 hour postinfection (hpi), and stained
with primary antibodies towardmajor outermembrane protein (MOMP) (red) andheat shock protein 60 (Hsp60) (green).DAPIwas used to detect bacterial and
hostDNA (blue). Confocal laser scanningmicroscopywas used to obtain the images. (C)HeLa cells infectedwithC. trachomatisLGV-2were treatedwithKSK120
or DMSO, and at 44 hpi, infectious progeny were collected for reinfection of new HeLa cells. DMSO treatment results were set to a value of 100. Data presented
were acquired from an experiment performed in triplicate. (D) Generation of infectious EB (elementary body) progeny of indicated C. trachomatis serovars in
the presence of 10 M KSK120 (44 hpi) or the corresponding amount of DMSO. Presented data are the means of the results of three experiments. (E)
Representative transmission electron micrographs of cells infected with C. trachomatis LGV-2 treated with 10 M KSK120 or the corresponding amount of
DMSO (44 hpi). (F) Growth and biofilm formation in the presence of KSK120. Results were quantified relative to nontreated E. coli results. Representative
experiments were performed in triplicate. In all figures, error bars indicate standard deviations (SD).
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pounds that inhibit the production of infectious progeny, we as-
sessed each compound for its effect on bacterial distribution
within the inclusion. We chose this assay because we previously
found that salicylidene acylhydrazide compounds, which cause a
reduction in the yields of infectious progeny, alter the normally
homogeneous distribution of bacteria within the inclusion to a
nonuniform and patchy distribution (15). Each compound, or a
dimethyl sulfoxide (DMSO) control, was added to HeLa cells im-
mediately after infection, and the distribution of bacteria within
inclusions was assessed at 44 h postinfection (hpi) using confocal
fluorescence microscopy. As expected, bacteria were homog-
enously dispersed inside the inclusions of DMSO-treated control
cells (Fig. 1B, left). In contrast, 3 compounds caused bacteria to be
heterogeneously dispersed, whereas 8 compounds caused moder-
ate heterogeneous dispersion and 12 were toxic to HeLa cells (see
Table S1). The remaining compounds had no effects on either
C. trachomatis distribution or the host cell.
We determined that large (e.g., phenyl) substituents in posi-
tion R1 had low activity (Fig. 1A, BibC4) whereas the smaller cy-
clopropyl substituent in position R1 resulted in compounds with
moderate activity that caused moderate heterogeneous bacterial
dispersion (e.g., BibC10; Fig. 1A). To improve the antichlamydial
activity of these compounds and to gain insight into the structure-
activity relationships, a small collection of 2-pyridones were syn-
thesized that retained cyclopropyl substitutions in position R1 but
differed in the substitutions at position R5 (Fig. 1A). Of these, the
KSK120 aryl amide derivative showed more activity than the
BibC10 parent compound in the bacterial dispersion assay
(Fig. 1B, right; see also Table S2 in the supplemental material),
whereas all other analogues showed lower activity or were toxic to
the host cell.
To verify that heterogeneous bacterial dispersion within inclu-
sions induced by KSK120 correlated with a reduction in levels of
infectious progeny, we collected lysates from infectedHeLa cells at
44 hpi and assessed the generation of infectious EB progeny by
determining the number of inclusion-forming units (IFUs).
KSK120 almost completely blocked the generation of IFUs at con-
centrations of 10 M and higher, with a 50% effective concentra-
tion (EC50) of 1.25M(Fig. 1C).Wenext investigated the effect of
KSK120 on different C. trachomatis serovars that cause a range of
human diseases, including invasive lymphogranuloma venereum
(LGV-2 serovar), urogenital infections (serovar D), and trachoma
(serovar A). Treatment with 10 M KSK120 nearly completely
blocked infectivity of all the three serovars, with ~10,000-fold-
fewer infectious EB progeny compared to the results seen with
DMSO-treated cells (Fig. 1D). Furthermore, inclusions in LGV-
2-infected cells treated with KSK120 contained reduced numbers
of RBs and EBs, although the remaining RBs and EBs were mor-
phologically similar in shape and size to those in untreated cells as
determined by transmission electron microscopy (Fig. 1E). Fur-
thermore, 50 MKSK120 did not affect the growth of uninfected
HeLa cells over a period of 48 h as assessed using a colorimetric
tetrazolium salt (XTT) cell proliferation assay (98.84%  2.35%
proliferation compared with HeLa cells grown in the absence of
KSK120), indicating that KSK120 has negligible host cell toxicity.
It was previously shown that a carboxylic acid in position R5 of
2-pyridones is critical for inhibition of E. coli biofilm formation
(16). We consistently observed that KSK120, which lacks the car-
boxylic acid, was unable to inhibit biofilm formation. In addition,
KSK120 did not inhibit growth of E. coli (Fig. 1F), indicating that
this compound does not generally affect bacterial physiology.
Thus, KSK120 showed selective antichlamydial activity with lim-
ited host cell toxicity, and we focused on it as a primary lead
inhibitor for further investigations.
KSK120 associates with the surface ofC. trachomatis LGV-2.
Fluorescent analogues of small-molecule inhibitors can be helpful
tools to identify their correspondingmolecular targets (17) and to
determine whether the primary target resides in the bacteria
themselves or in the host cell. Thus, we designed a fluorescent
analogue (EC364) by introducing a boron-dipyrromethene
(BODIPY) fluorophore into the molecule (Fig. 1A). The antichla-
mydial effect of EC364 inC. trachomatis LGV-2was indistinguish-
able from that of KSK120, with bacteria heterogeneously dis-
persed inside the inclusion of treated cells (see Table S1 in the
supplemental material) and a sharp drop in the generation of in-
fectious progeny (see Fig. S1A).
To determine the target of EC364 in C. trachomatis, infected
cells were treated at 18 hpi with EC364, fixed at 44 hpi, and im-
munostained with antibodies against the Chlamydia major outer
membrane protein (MOMP). EC364 associated mostly with bac-
teria in inclusions (see Fig. S1B in the supplemental material).
However, it was not possible to unambiguously assess the location
of staining within bacteria due to the small size of RBs. To circum-
vent this limitation, we employed a standardmethod, penicillin-G
treatment, to induce the enlargement of RBs (18). In penicillin-
G-treated C. trachomatis, EC364 clearly localized to distinct
puncta at the bacterial surface (Fig. 2). Moreover, EC364 sup-
pressed the enlargement of penicillin-G-treated C. trachomatis
when administered at 18 hpi (Fig. 2, middle row), possibly indi-
cating that these compounds interferewith acquisition of building
blocks required for RB enlargement in response to penicillin-G
treatment. All together, these data indicate that KSK120 binds to a
surface component(s) expressed in the RB form of C. trachomatis
that is essential for RBs to become infectious EBs.
Compound KSK120 affects G-6P metabolism in C. tracho-
matis. We next sought to identify potential pathways targeted by
KSK120 by isolating Chlamydia variants that are resistant to the
compound. This was accomplished by growing our wild-type
C. trachomatis LGV-2 strain in the presence of KSK120 for multi-
ple passages (Fig. 3A). Notably, prior KSK120 selection, our wild-
type C. trachomatis population had been passaged 20 times in
the laboratory and only one allelic variant in the uhpC gene was
identified by genome sequencing at a frequency of 10%, suggest-
ing that spontaneousmutations do not accumulate without selec-
tive pressures. After growing the wild type in the presence of
KSK120 for 15 passages, we sequenced the genomes of two clonal
plaque-purified KSK120-resistant strains and compared them to
the reference genome of LGV-2 (GenBank accession number
NC_010287) (19). Each strain contained the same four missense
mutations. Two were in uhpC (CTL0806; accession number
YP_001654877.1), which encodes the inner membrane hexose-
phosphate (G-6P) transporter UhpC (20) (nucleotide changes
G945T and G1285A, causing amino acid substitutionsM315I and
L429I, the latter of which was also present in a subpopulation at
the start of the selection). The third was in gene efp (CTL0121;
accession number YP_001654212.1), encoding elongation factor
P, or E-FP (nucleotide changes C391T, causing amino acid sub-
stitution R131C). The fourth was in rpoC (CTL0566; accession
number YP_001654642.1), encoding RpoC, the RNA polymerase
beta prime subunit (nucleotide change C3680A, causing amino
KSK120 Affects C. trachomatis G-6P Metabolic Processes
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acid substitution C1224F). We also genotyped four additional
clonal KSK120-resistant strains and found that three of them con-
tained all four mutations (in total, 5 strains with this genotype
were found), whereas one lacked the mutation in efp.
To reveal the order in which the mutations arose during selec-
tion, we estimated the percentage of bacteria in the population
with each mutant genotype at each passage (Fig. 3B). We deter-
mined that the UhpCL429I substitution was selected from the ini-
tial inoculumwhereas the other alleles appeared in the population
starting at passage 8 and increased in abundance over time. To
distinguish whether these mutations arose sequentially in a single
strain or separately in multiple strains, we performed a plaque
purification and genotyped 27 strains from passage 9. We found
that individual strains containedmutations in uhpC or efp but not
in both genes (see Table S3 in the supplemental material). Muta-
tions in rpoC were not detected. This suggests that each mutation
arose in a separate strain and later merged into a single strain
containing all four mutations, possibly by horizontal gene trans-
fer. As described below, this approach also allowed us to separate
individual strains bearing unique combinations of the identified
mutations (Table 1) for further characterization.
To gain further insight into the classes of mutations that can
confer KSK120 resistance, we initiated a second independent se-
lection for resistant mutants, starting with a clonal plaque-
purified wild-type strain that lacks any mutation in uhpC. We
grew this strain in the presence of increasing concentrations of
KSK120 for 10 passages and then sequenced the genome of a
mixed population of resistant variants (Fig. 3C). We identified
mutations in two genes.Onewas in pgi, encodingG-6P–isomerase
(CTL0633; accession number YP_001654706.1) (nucleotide
change A1133C, causing amino acid substitution H378P), an en-
zyme that catalyzes the first step of glycolysis in C. trachomatis
(21). The secondmutationwas in recC (CTL0008; accession num-
ber YP_001654099.1), encoding exodeoxyribonuclease V gamma
chain (nucleotide change C1474A, M415I substitution). The per-
centages of bacteria in the population with each mutant genotype
were 45% for the mutation in pgi and 19% for that in recC, sug-
gesting the presence of additional rare mutations in the popula-
tion. Next, we plaque purified and genotyped five clonal strains
from passage 10 and determined their genotypes at pgi and recC as
well as at uhpC, efp, and rpoC, since mutations in these genes had
been observed during previous selections (Fig. 3A). In these clonal
isolates, three strains contained the PgiH378P substitution, one
contained the RecCM415I substitution, and one contained a new
mutation in uhpC (nucleotide change G1180A, UhpCA394T)
(Fig. 3C). To determine which mutations would persist in the
population, we allowed further growth for 6 passages in the pres-
ence of KSK120. We observed that the mutations in pgi and recC
disappeared and the UhpCA394T variant emerged as the single pre-
dominant substitution (Fig. 3D). These data strongly suggest that
the majority of KSK120-resistant mutations arise in genes in-
FIG 2 A fluorescent analogue of KSK120 (EC364) associates with surfaces of penicillin-G-treated C. trachomatis LGV-2. Penicillin-G (100 U/ml) was added to
all infected cells at 18 hpi, concomitant with DMSO treatment (upper panels) or EC364 treatment (100M) (middle panels). EC364 treatment was also initiated
at 29 hpi (lower panels). At 44 hpi, infected cell were fixed with methanol and stained with primary antibody toward MOMP (red). DAPI was used to detect
bacterial and host DNA (blue). Confocal laser scanning microscopy was used to obtain images. DMSO-treated infections were used to define the background.
Engström et al.
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volved in G-6Pmetabolic processes and that KSK120 likely affects
this metabolic circuit.
To verify that the isolatedmutant strains are KSK120 resistant,
we quantified differences in the generation of infectious EBs be-
tween these mutant strains and wild-type Chlamydia organisms
after treatment with KSK120 (Table 1). Isogenic strains with a
mutation in uhpC, efp, pgi, or recC were shown to be directly
associated with KSK120 resistance because they produced 20-to-
250-fold-higher yields of infectious EBs in the presence of the
compound (Table 1). The high incidence of resistance mutations
in genes that are directly coupled toG-6Puptake and the first steps
of glycolysis (Fig. 3E) suggests that G-6P metabolic processes of
C. trachomatis are affected by KSK120 treatment.
KSK120affects glycogenaccumulation.Toexplore thepoten-
tial inhibitory effect of KSK120 on G-6P uptake and/or metabo-
lism, we assessed the consequences of the presence of the inhibitor
for bacterial glycogen levels, as glycogen biosynthesis is activated
when excess glucose is available (22) (Fig. 3E). Infected cells were
FIG 3 KSK120 affects G-6P metabolic processes of C. trachomatis. (A and C) Schemes showing at which mutant passages clonal strains were collected for
whole-genome sequencing (WGS) and/or genotyping in the respective selections. Wt, wild type. (A) First selection. (C) Second selection. (B and D) DNA was
isolated from mutant passages (bacterial populations), and the respective mutated regions were PCR amplified and subsequently genotyped by capillary
sequencing. Mutation frequencies were estimated from obtained chromatogram peak values. Peak values below 10% were omitted. (E) Bacterial pathways and
processes inwhichKSK120-resistantmutationswere identified.G-6Pmetabolic processes and downstream function are based on information from reference 28,
the function of E-FP is based on information from references 38 and 39, and RecC data are based on information from reference 40. Mutated proteins are
indicated in green, and the stars shown above the respective proteins indicate howmany different substitutions were identified from the mutant selections. The
mutation in rpoC increasedKSK120 resistance only slightly (Table 1); therefore, RpoCwas excluded from this figure. (F)C. trachomatisLGV-2-infected cells were
grown in the presence of the indicated compound and at 36 hpi were stained with iodine solution for detection of glycogen. IS-INP0341 is an abbreviation for
“iron-saturated INP0341.” Treatment with IS-INP0341 was included as a specificity control because this compound inhibits the generation of infectious EB
progeny in a manner identical to that of treatment with 5 MKSK120. Arrows indicate C. trachomatis inclusions.
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treated with KSK120 and stained with iodine, a standard method
for detection of glycogen buildup in C. trachomatis inclusions
(23). KSK120 abolished glycogen accumulation (Fig. 3F), consis-
tent with an inhibitory effect on G-6P uptake and/or metabolism.
Similar results were obtained with C. trachomatis serovar D (see
Fig. S2 in the supplemental material). The EC364 fluorescent
compound also reduced glycogen accumulation (see Fig. S3), in-
dicating that this analogue is relevant for showing KSK120 speci-
ficity and localization. As a control, we treated cells with iron-
saturated INP0341 (IS-INP0341), a compound that is not related
to KSK120 and that inhibits C. trachomatis development by tar-
geting heme metabolism (15). Although 30 M IS-INP0341 in-
hibited the generation of infectious C. trachomatis progeny to the
same extent as 5MKSK120, IS-INP0341 did not affect glycogen
accumulation. These data suggest that the effects of KSK120 on
G-6Pmetabolic processes are likely to be specific and not an indi-
rect consequence of its anti-Chlamydia activity.
Chemical genetics as a tool to investigate Chlamydia infec-
tivity. Chemical genetics is a tool that allows identification of tar-
get proteins and precise temporal control over their inhibition (9).
Nevertheless, there is a general lack of inhibitory compounds that
selectively target pathogens without affecting the normal micro-
biota. Here, we report the results of a novel visual screen for iden-
tifying inhibitory compounds that affect C. trachomatis infectiv-
ity. This screen identified KSK120, a 2-pyridone amide that
specifically affects C. trachomatis but not E. coli or host cells. Such
compounds might be helpful in gaining insights into bacterial
factors critical for chlamydial infectivity and may form the basis
for developing a new class of antichlamydial drugs (6, 7).
To identify the bacterial target(s) of KSK120, we selected for
resistantmutants and, for the first time inChlamydia spp., tracked
the acquisition of mutations step by step to monitor microevolu-
tionary trends. From our work and that of others, it is evident that
in vitro selection results in surprisingly few mutations in a C. tra-
chomatis population (15, 24). This allowed us to isolate a panel of
strains from intermediate or final selection passages that each con-
tained one mutation or a small number of mutations. Many of
these mutations mapped to genes involved in G-6P metabolism,
suggesting that this pathway is targeted by KSK120. We believe
that similar strategies could be applied to the study of other obli-
gate intracellular bacteria to understand how they adapt to new
environments and drugs.
Our data strongly support the notion that glucosemetabolism,
and G-6P transporter UhpC in particular, is targeted by KSK120.
This agrees with previous data that suggest that G-6P metabolic
processes are critical for Chlamydia infectivity (25–29). Thus,
KSK120 may prove useful for studying glucose metabolism in
Chlamydia spp., and its analogs may also be useful in other intra-
cellular bacteria. Importantly, host G-6P is available only to intra-
cellular bacteria and not to those that reside extracellularly. Thus,
KSK120 may represent a new class of drugs that can specifically
treat infections of intracellular bacterial pathogens such as Chla-
mydia while leaving the normal bacterial flora unperturbed.
MATERIALS AND METHODS
Synthesis and purification of ring-fused 2-pyridones.CompoundsC-10
methyl, C-10 CH2OH, VAC088, VAB086, VA140, VA142, and VA147
were synthesized according to published procedures (16, 30). All the other
compounds, except KSK120, were synthesized by basic hydrolysis of the
corresponding methyl ester-substituted 2-pyridones (31, 32).
General synthesis of KSK120. Compound C-10 methyl ester was ox-
idized by a previously reported method (33), and the product was hydro-
lyzed using lithium bromide (LiBr) and triethylamine (Et3N) in acetoni-
trile/water (98/2). After purification by column chromatography, the
product was dissolved in dry dichloromethane and cooled to 0°C. Oxalyl
chloride (1.5 Eq) was added dropwise, and the solution was allowed to
reach room temperature and stirred for 1 h. After the evaporation of
solvent to remove HCl, the residue was redissolved in dichloromethane,
followed by the addition of triethylamine (3 Eq) and aniline (2 Eq). The
solution was continuously stirred for 4 h and then concentrated and pu-
rified by column chromatography on a silica gel (see Text S1 in the sup-
plemental material for the additional chemical experimental procedure
details).
Chemicals and ring-fused 2-pyridones. 2-Pyridones and the sali-
cylaldehyde hydrazone INP0341 (34) were dissolved in dimethyl sulfox-
ide (DMSO; Sigma) to reach a final concentration of 20mM and stored at
room temperature without exposure to light for amaximumof 2months.
Prior to experiments, the compounds were diluted in prewarmed RPMI
media. Penicillin-G was dissolved in water to reach a concentration of
80,000 U/ml and filter sterilized (Millipore) (0.22-m-pore-size filter).
Compound INP0341 was iron saturated by mixing equal amounts of
compound and FeCl3. The mixture was incubated for 1 h at room tem-
perature before being added to prewarmed RPMI media.
E. coli growth and biofilm assays. E. coli clinical isolate UTI89 was
statically grown in Luria broth for 24 h at 37°C, and optical density (OD)
was measured at a wavelength of 600 nm (OD600). For the biofilm assay,
E. coli was statically grown in Luria broth for 48 h at 26°C and thereafter
stained with crystal violet as already described (13). Absorbance wasmea-
sured at OD600.
Cell culture, C. trachomatis infections, plaque assay, and cell toxic-
ity assay. The HeLa cell line (DSMZ) was grown at 37°C (5% CO2) in
RPMI 1640 (Sigma) supplemented with 10% fetal bovine serum (FBS)
(Sigma) and 20mMHEPES. Vero cells (ATCC)were grown inDulbecco’s
TABLE 1 Collected clonal C. trachomatis strains and their KSK120 susceptibility
Strains with indicated substitution(s)a Fold increase in infectious EBsb Mutant passage (P), parental strain
Wild type 1 (0.38) Wild-type population
UhpCL429I 18.7 (1.33) Wild-type population
UhpCL429I, M315I 141 (19.2) P9, wild-type population
UhpCA394T 205 (42.65) P10, clonal wild type
PgiH378P 74.44 (17) P10, clonal wild type
RecCM415I 118 (20.1) P10, clonal wild type
EF-PR131C 186.83 (19.61) P9, wild-type population
UhpCL429I, M315I, RpoCC1224F 242.52 (30.38) P15, wild-type population
UhpCL429I, M315I, RpoCC1224F, EF-PR131C 169.86 (23.76) P15, wild-type population
a Isolated by plaque purification, lacking the other identified mutations.
b Infectious EB progeny generated (at 44 hpi) in the presence of 10 MKSK120, normalized to input inclusion-forming units (IFU). The values for the wild type were set to 1.
Representative data are from an experiment performed in triplicate SD.
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modified Eagle’s medium (DMEM) (Gibco/Invitrogen) supplemented
with 10% FBS (Sigma) at 37°C (5% CO2). Chlamydia trachomatis serovar
LGV-L2 454/Bu (ATCCVR902B),C. trachomatis serovar D (a gift from S.
Muschiol), and C. trachomatis serovar A (ATCC VR571B) were propa-
gated in HeLa cells in the absence of cycloheximide, and elementary bod-
ies was purified as previously described by Caldwell et al. (35) and stored
in SPG buffer (0.25 M sucrose, 10 mM sodium phosphate, 5 mM
L-glutamic acid). For infection experiments, HeLa cells were infected by
C. trachomatis diluted in Hanks balanced salt solution (HBSS) (Gibco/
Invitrogen) with a multiplicity of infection (MOI) of 0.01 to 1 for 1 h at
37°C (5% CO2). HBSS was subsequently removed, and complete RPMI
media supplemented with the indicated compounds were added to the
infected cells. Cycloheximide was excluded in all experiments. Clonal
populations were collected by plaque assay as described elsewhere (36).
Briefly, Vero cells were infected with 100 to 10 IFUs for 2 h and infected
cells were overlaid with an agarose-DMEM overlay. Plaques were col-
lected 10 to 20 days after infection and propagated in HeLa cells. Vero
cells, HeLa cells, andC. trachomatis strains were negative for mycoplasma
infection as determined by a detection kit according to themanufacturer’s
instructions (Stratagene). Cell viability was analyzed using an XTT cell
proliferation kit acquired from ATCC. Compound KSK120 was added in
triplicate at a concentration of 50M.After 24 and 48 h, the XTTmixture
was added to the wells according to the manufacturer’s instructions
(ATCC) and incubated at 37°C for 2.5 h. Subsequently, the plates were
read at 470 nm and 660 nm. The results seen with HeLa cells that prolif-
erated in the absence of the compound were set to a value of 100.
Phenotypic screen and immunofluorescence. Semiconfluent HeLa
cells grown on coverslips were infected as described above. The com-
pounds presented in Table S1 in the supplemental material were at first
tested at a concentration of 100M, and treated infections were observed
by light microscopy for 44 h. Treated samples were subsequently fixed
with methanol for 5 min, background fluorescent signals was reduced by
blocking the samples with 5% bovine serum albumin for at least 1 h, and
the samples were thereafter incubated with primary anti-MOMP anti-
body (a gift from Ken Fields) and primary anti-Hsp60 antibody (Santa
Cruz Biotechnology). Next, a lissamine rhodamine sulfonyl chloride
(LRSC)-conjugated anti-rabbit antibody was used to detect the MOMP
antibody and a fluorescein isothiocyanate (FITC)-conjugated anti-mouse
antibody (both from Jackson ImmunoResearch Laboratories) was used to
detect the Hsp60 antibody. DNA was stained with 200 nM DAPI (4=,6-
diamidino-2-phenylindole). Coverslipsweremounted on glass slideswith
fluorescence mounting media (Dako). Images were obtained by confocal
laser scanning microscopy (Nikon Eclipse C1 plus) and processed by the
use of Adobe Photoshop software (Adobe Systems Inc.). The effect of the
compounds was scored based on the distribution of C. trachomatis inside
the inclusion, before and after fixation. The heterogeneous bacterial dis-
tribution inside the chlamydial inclusion was equivalent to a strong phe-
notypic effect.
Localization of aKSK120 fluorescent analogue.At 18 hpi, RPMIme-
dia were changed to media supplemented with 100 Mof the fluorescent
analogue EC364. DMSO was used as a control. At 44 hpi, infected cells
were washed twice with phosphate-buffered saline (PBS) and then fixed
with methanol or 4% paraformaldehyde and stained with the anti-
MOMP antibody andDAPI as described above. Penicillin-Gwas added at
18 hpi, at a concentration of 100 U/ml, and EC364 was added either
concomitantly (18 hpi) or at 29 hpi. Images were obtained and processed
as described above.
Determination of C. trachomatis infectivity. At the indicated time
point, media were completely removed and the infected cells were dis-
rupted with ice-cold sterile water to release infectious EB progeny. Re-
leased bacteria were diluted in HBSS, fresh HeLa cells were infected, and
the C. trachomatis inclusions were counted 30 to 40 h after reinfection.
Data are represented as the relative numbers of EBs in treated infections
compared to the numbers of EBs inDMSO-treated infections.Whenmul-
tiple strains were analyzed, a titration was performed in parallel to the
primary treated infections to calculate the exact number of infectious EB
progeny per treated IFU (36).
Glycogen staining. Potassium iodine and iodine (both from Sigma)
were dissolved in 100% methanol. Subsequently, an equal amount of
glycerol was added to the solution. At time points postinfection, culture
media were removed and infected cells were washed once with PBS before
incubation in iodine solution for 30 min. Thereafter, the iodine solution
was removed and samples were air-dried for 90 min prior to microscopic
analysis (37). Samples were visualized using an inverted Nikon Eclipse Ti
microscope.
Mutant selections.HeLa cells grown in large flasks were infected with
an MOI of 5 (~108 IFUs) and treated with a subinhibitory concentration
of compound KSK120. From eachmutant passage, infectious EB progeny
were collected at 44 to 48 hpi and used for reinfection. During the first 4 to
6 passages, the treated bacteria were grown at an MOI of 2 or higher;
thereafter, the selection proceeded with an MOI of 2 or lower (preferen-
tially lower than an MOI of 1). From each mutant passage, an aliquot of
bacteria was saved for analysis.
WGS and genotyping. C. trachomatis genomic DNA prepared for
whole-genome sequencing (WGS) was purified from density-gradient-
purified bacteria as described above. ForWGS, 1g of enriched chlamyd-
ial DNAwas fragmentedwith anAdaptive FocusedAcoustics S220 instru-
ment (Covaris, Inc., Woburn, MA), and DNA sequencing libraries were
preparedwith a library construction kit (TruSeqDNA sample preparation
kit v2; Illumina, Inc., San Diego, CA) according to the manufacturer’s
instructions. Libraries were sequenced on aMiSeq DNA sequencing plat-
form (Illumina, Inc., San Diego, CA) at the IGSP DNA Core sequencing
facility of Duke University. Genome assembly and single nucleotide vari-
ant (SNV) identification were performed with Geneious version 6 from
Biomatters. The C. trachomatis L2 434/Bu genome (GenBank accession
no. NC_010287) was used as the reference sequence. A mutation is de-
fined here as a nucleotide variant present at a frequency above 15% and
strand bias below 80%, detectable by bothWGS and capillary sequencing
in a bacterial population. To identify mutations by capillary sequencing,
templates from selected regions were amplified by PCR and sequenced by
capillary sequencing (Big Dye; Applied Biosystems). The intensity of the
fluorescence peaks detected by capillary DNA sequencing was used to
estimate the relative abundance of any single nucleotide variant in the
bacterial population. Estimated frequencies were consistent with the val-
ues obtained fromWGS.
Transmission electron microscopy (TEM). At 44 hpi, infected cells
were processed for TEM as previously described (36). Briefly, cells were
fixed with 2.5% glutaraldehyde–0.05% malachite green–0.1 M sodium
cacodylate buffer (pH 6.8) and then postfixed with 0.5% osmium tetrox-
ide–0.8% potassium ferricyanide–0.1 M sodium cacodylate–1% tannic
acid–1% uranyl acetate. Samples were dehydrated with graded amounts
of ethanol and embedded in Spur resin and were subsequently imaged on
a Tecnai G2 Twin microscope (FEI).
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